SCHEMBL20495290

SCHEMBL20495290

Nc1cc(-c2cc(F)ccc2F)ccc1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.49
ALDH1A1 P00352 5/20 0.47
HSD17B10 Q99714 5/20 0.47
ALOX15 P16050 4/20 0.47
HPGD P15428 3/20 0.47
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 2/20 0.47
USP2 O75604 2/20 0.47
LMNA P02545 2/20 0.47
KMT2A Q03164 2/20 0.47
ALOX12 P18054 2/20 0.47
HSP90AA1 P07900 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
HTT P42858 1/20 0.47
CA3 P07451 1/20 0.45
CA6 P23280 1/20 0.45
CA5A P35218 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13652988 0.86 ALDH1A1 (0.59) NPC1ALDH1A1HSD17B10ALOX15HPGD
SCHEMBL5843743 0.86 HSD17B10 (0.55) NPC1ALDH1A1HSD17B10ALOX15HPGD
SCHEMBL21369192 0.79 ALDH1A1 (0.67) NPC1ALDH1A1HSD17B10ALOX15HPGD
SCHEMBL101785 0.78
SCHEMBL21857737 0.77 HSD17B10 (0.59) ALDH1A1HSD17B10ALOX15HPGDKDM4E
Hydrochloric Acid SCHEMBL27546033 0.76 ALDH1A1 (0.50) NPC1ALDH1A1HSD17B10ALOX15HPGD
SCHEMBL16428806 0.76 CA3 (0.50) NPC1ALDH1A1HSD17B10ALOX15HPGD
SCHEMBL7556230 0.75 TAAR1 (0.50) ALDH1A1HSD17B10LMNAMAPTHTT
SCHEMBL24786055 0.75 HSD17B10 (0.61) ALDH1A1HSD17B10ALOX15HPGDKDM4E
SCHEMBL24766983 0.74 CA3 (0.44) ALDH1A1CA3CA6CA5ACA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200207726-A1 INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE LYCERA CORPORATION 2020-07-02 US disclosed
US-20200207726-A1 INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE LYCERA CORPORATION 2020-07-02 US disclosed
WO-2018165501-A1 INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATMENT OF DISEASE LYCERA CORPORATION (US) 2018-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200207726-A1 INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE RORA, RORC, RORB NPC1 2694/4885ALDH1A1 1034/4885HSD17B10 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.